); d) lack of regular attendance in the intervention; e) COVID-19 infection Intervention groups: a

methanol Pregnant women Patients suspected of Covid-19 infection Intervention groups: Intervention group

willingness to continue participation. Diagnosis of COVID-19. Attending clinic for reasons other than

6- Ability to use mobile smart phone 7- History of not being infected with Quid-19 Exit conditions 1

Study aim: Evaluation of Immunogenicity and safety of Noora vaccine as a booster. Design: This clinical trial is designed as a hybrid (in the form of two separate trials) in phase 3: ّ First A randomized, double blind clinical trial with two parallel groups and a single center with a sample size of 300 people. Second A multicenter and single arm clinical trial comparing before and after injection of booster vaccine with a sample size of 10000 people. Settings and conduct: The first part in the single center of Shahid Soleimani will be randomly double blind with parallel groups to check the immunogenicity . Blinding ratio will be 1: 2 and the volunteer, researcher and executive staff are unaware of the nature of the injection. The second ward will be in one of the 10 affiliated centers of Baqiyatallah Hospital, before and after. After injection, possible allergic reactions and other reactions will be recorded. Participants/Inclusion and exclusion criteria: Inclusion criteria include: over 18 years of age, candidates who have received two identical doses of the specified approved vaccine by MOH, and at least 3 months after the second dose, fully understand the provisions of the consent form and sign it. Exclusion criteria include: COVID19 infection in the past two months, quarantine, history of certain diseases, medication received in the last 3 months, receiving immunoglobulin or blood products in the previous 3 months, pregnant women Or breastfeeding or intending to pregnancy Intervention groups: Including two intervention groups 1) Injection of 80 μg of recombinant RBD protein vaccine 2) Injection of a placebo dose Main outcome variables: Primary Outcomes: Comparison of antibody levels in a sample of 300 volunteers on days 0 and 21 after injection. Cell immune response to booster dose and measurement of neutralized antibody level in 90 subgroups.

Study aim: Evaluating Immunogenicity and safety of recombinant SARS-COV-2-S protein Design: A phase II, randomized, two-armed, double-blind, placebo controlled clinical trial with 400 subjects. Stratified randomization by R-CRAN-version 4.0.1 Settings and conduct: randomized, two-armed, double-blind, placebo controlled clinical trial in Espinas Palace Hotel, Tehran Participants/Inclusion and exclusion criteria: inclusion:Individuals≥18 years.who are willing and able to comply with study requirements.Healthy and stable medical conditions.Women who are not pregnant/breastfeeding.exclusion:Subjects with active infection with signs of SARS-COV-2.Subjects with temperature ≥38◦C at screening or 72hrs prior.Progressive/severe neurological disorder,seizures,history of Guillain-Barre syndrome.who receive immunosuppressive medications.Pregnant/breastfeeding or women who become pregnant during the study.People with history of severe adverse reactions to the study vaccine.who participated in clinical trials within 30 days before screening until end of the study.who have previously vaccinated against SARS-CoV-2.who received other authorized vaccines within 28 days prior to the screening/intend to receive vaccine up to 14 days after second dose.People with known bleeding disorder.who received/intend to receive any blood/blood products 90 days or donated ≥450ml 28 days prior to screening Intervention groups: Intervention:1 IM injection of 25 ug subunit vaccine with Advax-CpG adjuvant on day 0 and 21 Placebo:1 IM injection of normal saline (0.9% saline) on day 0 and 21 Main outcome variables: solicited adverse events up to 7 days after each dose. unsolicited adverse events up to 28 days after each dose Evaluation and comparison of individuals with seroconversion for IgG bAb against S protein on days 21 and 35. GMT measurement for IgG binding antibody (bAb) against protein S on days 0, 21 and 35

Study aim: Determination of the effect of vitamin A on respiratory sign and hospitalization duration inn patients with covid19 Design: two arm, parallel group randomized controlled trial Settings and conduct: This study will be conducted in Imam Reza hospital, affiliated with Tabriz University of medical sciences. based on inclusion criteria 30 patients will be selected and respiratory signs and saturation rate will be recorded at the first day of hospitalization. then he patients will randomly divided to two groups of 15 patients. in vitamin A group, the patients will receive 50000 dose of vitamin A along with routine treatments and in the control group, The patients will receive only the routine treatments. after two weeks the respiratory sing, saturation rate and hospitalization days will be recorded Participants/Inclusion and exclusion criteria: Inclusion criteria: confirmed diagnosis of COVID19 with RT-PCR; hospitalized patients; ventilator independent patients; Exclusion criteria: being pregnant; lactating mothers; not consent to participate in the study; using high-dose vitamin A in last month. Intervention groups: Vitamin A group will be include 15 patients with COVID19 that will be treated with vitamin A 50000 along with routine treatment for two weeks Control group will also include 15 patients with COVID19 that will be treated with only routine treatment for two weeks Main outcome variables: Hospitalization duration respiratory signs

the glottis is recorded and measured. Success in intubation is also recorded in both groups. Covid box

Study aim: The aim of this study was to investigate the effect of social network-based cognitive-behavioral therapy intervention on the severity of PMS symptoms. Design: Clinical trial with control group, with randomized parallel groups, without blinding, phase 3 on 140 patients Settings and conduct: This randomized controlled trial study will be performed in comprehensive health centers affiliated to Guilan University of Medical Sciences, Rudbar city. The social media -based CBT program will be provided in 8 consecutive weeks within 14 separate sections of introductory, cognitive strategies, suggestions for behavioral lifestyle changes, and ends with relapse prevention. The Cognitive Strategies provides information and strategies for identifying and correcting dysfunctional cognitions, especially specific PMS cognitions and specific PMS behaviors and misconceptions. The other sections include suggestions for lifestyle changes such as stress reduction, exercise, and diet Cover a balanced diet. In the last section, a summary and a plan to protect the benefits and prevent returns is provided. All sections include practical exercises for applying and practicing theoretical content. Blinding will be done according to the nature of the study. Control group will receive no intervention. Participants/Inclusion and exclusion criteria: Willingness to participate in the study; Age 45-20 years; Moderate to severe premenstrual syndrome; Internet access; Having a smartphone Intervention groups: The intervention group will receive social network-based cognitive-behavioral therapy for 8 consecutive weeks consisting of 14 separate sections including introductions, cognitive strategies, and suggestions for behavioral lifestyle changes and relapse prevention. Control group will receive no intervention. Main outcome variables: Severity of premenstrual syndrome symptoms

2 and Wagner grade 1 and 2 diabetic foot ulcers; Exclusion criteria: Getting infected with covid 19

techniques, Covid-19 infection during the study or during one month before the start of the study, carpal

, endocrine, or chronic diseases, covid-19, or any kind of infection; Not hospitalized, has not used

(type 2 diabetes, COVID-19 infection), The occurrence of MS attack, Smoking (at least two cigarettes per

Study aim: The effect of L-carnitine supplementation on mortality and serum levels of C-reactive protein in obese patients with coronavirus (nCov-2019) with acute respiratory failure admitted to the intensive care unit Design: Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 on 40 patients. Numbers in closed envelopes were used for randomization. Settings and conduct: A total of 40 adult patients with acute coronavirus-induced respiratory infection admitted to the Army Hospital ICU referred by an Intensive Care Specialist will be enrolled in the study after obtaining informed consent to participate in the study. Entry of each patient into the case or control group will be random and with the help of numbers in closed envelopes. Commercial L 3-carnitine capsule supplement with a dose of 3000 mg and starch as a placebo that is randomly packed and covered (blinding) is gavaged to patients for 7 days. Participants/Inclusion and exclusion criteria: Obese men and women; over the age of 18; with acute respiratory failure due to coronavirus; hospitalized in the intensive care unit; individuals who wish to participate if they have no history of liver or kidney disease and are not pregnant or breastfeeding. Intervention groups: Oral supplement with a high dose of L- carnitine (3000 mg) in patients with acute coronavirus-induced respiratory infection in the intensive care unit Main outcome variables: Evaluation of ICU mortality, 28-day mortality, serum level of acute-phase reactive protein CRP, the ratio of serum level of acute-phase reactive protein level C to albumin, the number of ventilator-dependent days

chronic diseases, covid-19, or any kind of infection; Not hospitalized, has not used antibiotics, curcumin

participating in other interventional studies Patients with COVID-19 in admission Intervention groups: In the

Study aim: The effect of 16 weeks of concurrent home-based exercise on cortisol levels, resting heart rate, quality of life, cancer-related fatigue, body image, cognitive function, cardiovascular endurance, upper and lower body strength, flexibility, and body composition Design: A randomized clinical trial with a control group, parallel groups on 28 breast cancer patients, block randomization via www.randomization.com Settings and conduct: This study is conducted at Ilam University with the cooperation of Ilam University of Medical Science. After selecting the participants according to inclusion criteria, the study variables are measured, and then, the experimental group will perform 16 weeks of exercise interventions at home supervised by a specialist via video call. After the termination of the intervention, the variables are measured again. According to the nature and the objectives of the study, blinding will not be applied. Participants/Inclusion and exclusion criteria: Inclusion Criteria: Diagnosed with breast cancer by a specialist No less than 3 months and more than 5 years passed from the last cancer-specific treatment Exclusion Criteria: Cardiovascular and pulmonary disease Musculoskeletal disorder Intervention groups: Intervention group: this group will perform home-based concurrent training 2 times per week for 16 weeks. The training program consists of 3 phases including A (4 weeks), B (6 weeks), and C (6 weeks). Each training session consists of body-weight resistance training followed by step aerobic. During 16 weeks, the intensity, time, and volume of training will increase gradually. Control group: this group will have a normal life during the study Main outcome variables: Changes in cortisol levels, resting heart rate, quality of life, cancer-related fatigue, body image, cognitive function, cardiovascular endurance, upper and lower body strength, flexibility, and body composition

Study aim: The recombinant SARS-CoV-2-S protein vaccine (SpikoGen®) in individuals aged 5-18 and adults aged 18-40 is non-inferior in immunogenicity and it has acceptable safety Design: A non-randomized,three-armed,non-inferiority,open label,parallel clinical trial with 810 volunteers in 3groups aged5-12,12-18 and 18-40 Settings and conduct: Non-randomized,three-armed,non-inferiority,open label,parallel in Orchidlife of Orchidpharmed Co. Participants/Inclusion and exclusion criteria: Inclusion:Individuals5-40years; who are able to comply with study requirements;Healthy and stable medical conditions;Women who are not pregnant or breastfeeding;Individuals aged 5-18, body mass index should be equal percentile or higher, according to WHO standards.Exclusion:Subjects with active infection with signs of SARS-COV-2;People with epilepsy or a history of febrile seizure;Receive immunosuppressive medications;People with history of severe adverse reactions to the vaccine;Who participated or intend to participate in clinical trials within 30 days before screening until end of the study.Who have previously vaccinated against SARS-CoV-2;Who received other authorized vaccines within 28 days prior to the screening/intend to receive vaccine up to 14 days after second dose;People with known bleeding disorder;People with special circumstances who,in the researcher's view,may increase the risk of participating in the study;Who received/intend to receive any blood/blood products 90 days or donated ≥450ml 28 days prior to screening. Intervention groups: children aged5-12:1IM injection of12.5µg SpikoGen individual aged12-40:1IM injection of25µg SpikoGen on days0,21 Main outcome variables: Evaluation of non-inferiority of neutralizing antibodies seroconversion in children aged 5-12,adolescents aged 12-18 and adults aged 18-40 by Conventional virus neutralization test(cVNT) two weeks after the second dose

complementary therapies. Diagnosed with COVID-19 during the trial. Pregnancy, lactation and menopause. Using

during the study3-Break and not using the retainer 4-Specific conditions of COVID 19 infection that

Study aim: Effect of Functional Exercise Along with online Nutritional Education on Inflammatory-Oxidative and Metabolic Profile in Children with Autism Spectrum Disorder during Covid-19 Pandemic Design: Randomized clinical trial with parallel groups on 80 children with autism spectrum disorder Settings and

Study aim: To examine the effects of mouthwash containing pomegranate peel extract (punica granatum) and chlorhexidin 0.2% on the prevention of ventilator associated pneumonia in patients admitted to intensive care units Design: This is a single blind randomized controlled clinical trial. A total of 120 eligible patients will be selected based on convenience sampling. The researchers will allocate them to experimental and control groups using block randomization. Settings and conduct: This is a single blind RCT (an assessor blind trial) in which a total of 120 patients to be admitted to ICUs will be selected based on convenience sampling method. The researchers will allocate them to experimental and control groups using block randomization. Participants/Inclusion and exclusion criteria: Inclusion criteria: patients aged 18-65 years having a tracheal tube up to 12 hours to elapse after ICU admission Exclusion criteria: tracheostomy tube reintubation Intervention groups: In the experimental group, the nurse will apply 20 CC of 5% pomegranate peel extract mouthwash twice a day using a syringe. Then, she cleanses the teeth, tongue, gum, and oral mucosa and simultaneously suctions the mouth and pharynx for 30 seconds. Finally, she moisturizes the lips with A+D moisturizing cream. If there is an airway, she will remove and clean it and put it back in the mouth. In the control group, the nurse will apply 10 CC of 0.2% chlorhexidine mouthwash solution twice a day on the teeth, tongue, gum, and oral mucosa and simultaneously suctions the mouth and pharynx for 30 minutes. Main outcome variables: Pneumonia severity

Study aim: Comparison of the antibacterial effect of tetracycline gel and gel containing mesoporous silica nanoparticles loaded with tetracycline in the gingival groove fluid at the junction of implant and abutment Design: A trial will include a group with three samples per person, two test implants, and one control implant (without medication). Settings and conduct: According to the defined entry and exit criteria, 18 patients who need at least 3 mandibular implants are included in the study. In the uncovering session, tetracycline gel and gel containing mesoporous silica nanoparticles loaded with tetracycline are placed in two fixtures and no other substance is applied in the another fixture. Then, in three sessions of prosthesis impression, prosthesis delivery and one month after delivery, a sample of gingival groove fluid is prepared using a paper point and sent to the microbiology laboratory to measure the amount of bacteria present. Participants/Inclusion and exclusion criteria: 1.At least 3 implants in one jaw,minimum age of 18 years,pocket depth of implant 1-3,supra gingival margin,At least 4 months have passed since the extraction of the replacement teeth 2.Breastfeeding,Pregnancy,Patients receiving antibiotics in the last 6 months,systemic disease that affects oral health,Addiction,allergy to tetracycline,People with coronavirus and suspected of it,patients need graft and bone reconstruction,9- Presence of periodontal disease in other Intervention groups: There will be two test implants (tetracycline gel and nanoparticle gel containing tetracycline) and one control implant (without any medication) Main outcome variables: Ability to reduce microbial load and prevent pre-implantitis

Study aim: Assessing the effect of genetical nanocomposit drug with cell immunity level on human coronavirus (COVID-19) Design: Clinical trial with control group, with parallel groups, non-randomly assigned to intervention and control groups, Phase 1-2, 30 patients Settings and conduct: This clinical trial

certain medicinal plants; having problems such as nasal congestion; loss of sense of smell due to Covid-19